[go: up one dir, main page]

NO930440D0 - Tri- og tetravalente monospesifikke antigen-bindingsproteiner - Google Patents

Tri- og tetravalente monospesifikke antigen-bindingsproteiner

Info

Publication number
NO930440D0
NO930440D0 NO930440A NO930440A NO930440D0 NO 930440 D0 NO930440 D0 NO 930440D0 NO 930440 A NO930440 A NO 930440A NO 930440 A NO930440 A NO 930440A NO 930440 D0 NO930440 D0 NO 930440D0
Authority
NO
Norway
Prior art keywords
tri
antigen binding
binding proteins
monospecific antigen
proteins
Prior art date
Application number
NO930440A
Other languages
English (en)
Other versions
NO930440L (no
Inventor
David John King
Alison Turner
Nigel Robert Arnold Beeley
Thomas Andrew Millican
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd filed Critical Celltech Ltd
Publication of NO930440D0 publication Critical patent/NO930440D0/no
Publication of NO930440L publication Critical patent/NO930440L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO93930440A 1991-06-11 1993-02-09 Tri- og tetravalente monospesifikke antigen-bindingsproteiner NO930440L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919112536A GB9112536D0 (en) 1991-06-11 1991-06-11 Chemical compounds
PCT/GB1992/001047 WO1992022583A2 (en) 1991-06-11 1992-06-11 Tri- and tetra-valent monospecific antigen-binding proteins

Publications (2)

Publication Number Publication Date
NO930440D0 true NO930440D0 (no) 1993-02-09
NO930440L NO930440L (no) 1993-04-02

Family

ID=10696461

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930440A NO930440L (no) 1991-06-11 1993-02-09 Tri- og tetravalente monospesifikke antigen-bindingsproteiner

Country Status (15)

Country Link
EP (1) EP0560947B1 (no)
JP (1) JP3373849B2 (no)
KR (1) KR930701490A (no)
AT (1) ATE192457T1 (no)
AU (1) AU1971692A (no)
CA (1) CA2088367C (no)
DE (1) DE69230994T2 (no)
DK (1) DK0560947T3 (no)
ES (1) ES2146212T3 (no)
FI (1) FI930580L (no)
GB (1) GB9112536D0 (no)
NO (1) NO930440L (no)
NZ (1) NZ243099A (no)
WO (1) WO1992022583A2 (no)
ZA (1) ZA924271B (no)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2278357B (en) * 1992-12-10 1997-03-05 Celltech Ltd Humanised antibodies directed against A33 antigen
DE4310141A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Homobidentale trifunktionelle Linker
DE4310142A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Immunologisch aktive Konjugate und ein Verfahren zu ihrer Herstellung
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
ATE518885T1 (de) 2002-05-28 2011-08-15 Ucb Pharma Sa Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
ES2382879T3 (es) 2005-09-14 2012-06-14 Ucb Pharma, S.A. Conjugado de anticuerpo - polímero de peine.
NZ569234A (en) 2005-12-09 2011-07-29 Ucb Pharma Sa Antibody molecules having specificity for human IL-6
US8293500B2 (en) 2006-03-22 2012-10-23 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
JP4780405B2 (ja) * 2006-08-29 2011-09-28 アイシン精機株式会社 結合親和性を利用する被検物質の測定方法、及び被検物質の測定のための結合親和性解析の制御方法
EP1897886A1 (en) * 2006-09-08 2008-03-12 Bayer Schering Pharma Aktiengesellschaft Compounds as aptamer-dimers and their uses in diagnosis and therapy
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
BRPI1008692B8 (pt) 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
US8734798B2 (en) 2009-10-27 2014-05-27 Ucb Pharma S.A. Function modifying NAv 1.7 antibodies
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2380909A1 (en) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
CN101962503B (zh) * 2010-08-27 2013-01-02 东华大学 耐高温电磁线自粘漆及其制备方法
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
ES2632583T3 (es) 2011-01-14 2017-09-14 Ucb Biopharma Sprl Anticuerpo que se une a IL-17A e IL-17F
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
WO2013007388A1 (en) 2011-07-13 2013-01-17 Ucb Pharma, S.A. Bacterial host strain expressing recombinant dsbc
PT2758432T (pt) 2011-09-16 2019-06-14 Ucb Biopharma Sprl Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
MX351502B (es) 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2793949B1 (en) 2011-12-23 2018-08-22 Innate Pharma Enzymatic conjugation of antibodies
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
EP2786766A1 (en) * 2013-04-05 2014-10-08 Ufpeptides S.r.l. Supramolecular aggregates comprising maleimido cores
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TN2016000525A1 (en) 2014-05-29 2018-04-04 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CU20170041A7 (es) 2014-09-26 2017-09-06 Macrogenics Inc Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
BR112017023158A2 (pt) 2015-04-30 2018-07-24 Harvard College anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CN107660152B (zh) 2015-05-27 2021-11-05 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
SG10202010506TA (en) 2015-07-30 2020-11-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
WO2017060242A1 (en) 2015-10-05 2017-04-13 Ucb Biopharma Sprl Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
HK1251475A1 (zh) 2015-10-08 2019-02-01 Macrogenics, Inc. 用於癌症治疗的联合疗法
MY206805A (en) 2015-10-27 2025-01-08 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US20170198051A1 (en) 2016-01-11 2017-07-13 Inhibrx Lp Multivalent and multispecific ox40-binding fusion proteins
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
SG11201901597UA (en) 2016-08-26 2019-03-28 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
KR102630036B1 (ko) 2016-12-23 2024-01-29 마크로제닉스, 인크. Adam9-결합 분자, 및 이것의 사용 방법
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
BR112019023249A8 (pt) * 2017-05-05 2021-02-23 Centre For Probe Dev And Commercialization anticorpos monoclonais igf-1r e usos dos mesmos
IL270453B2 (en) * 2017-05-05 2025-05-01 Fusion Pharmaceuticals Inc Pharmacokinetic enhancements of bifunctional chelates and uses thereof
EP3624848A1 (en) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Combination therapies
CN107652219B (zh) * 2017-08-14 2021-06-08 上海新理念生物医药科技有限公司 四马来酰亚胺型连接子及其应用
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
EP3752196A4 (en) 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
EP3806898B1 (en) 2018-06-18 2025-10-08 UCB Biopharma SRL Gremlin-1 antagonist for use in the treatment of cancer
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
CN112601761A (zh) 2018-08-13 2021-04-02 印希比股份有限公司 结合ox40的多肽及其用途
EP3866933A1 (en) 2018-10-16 2021-08-25 UCB Biopharma SRL Method for the treatment of myasthenia gravis
AU2020247175A1 (en) 2019-03-26 2021-10-14 Aslan Pharmaceuticals Pte Ltd Treatment employing anti-IL-13R antibody or binding fragment thereof
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
TW202140563A (zh) 2020-02-21 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌ－２抗體、其抗原結合片段及其醫藥用途
AU2021224787A1 (en) 2020-02-21 2022-10-06 Macrogenics, Inc. CD137 binding molecules and uses thereof
EP4151655A1 (en) 2020-05-14 2023-03-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
CN114269790B (zh) 2020-07-02 2023-11-24 北京拓界生物医药科技有限公司 抗FXI/FXIa抗体、其抗原结合片段及医药用途
US20240279353A1 (en) 2020-07-06 2024-08-22 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
KR20230044275A (ko) 2020-07-27 2023-04-03 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 항-cd79b 항체-약물 접합체, 및 이의 제조 방법 및 이의 약학적 용도
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules that multimerise cd45
WO2022089767A1 (en) 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
IL303294A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Antibodies against interleukin-22
AU2021395729A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
CA3216034A1 (en) 2021-04-25 2022-11-03 Xiaofeng Yang Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
CA3218933A1 (en) 2021-05-03 2022-11-10 UCB Biopharma SRL Antibodies
WO2022235768A1 (en) 2021-05-04 2022-11-10 Sachem, Inc. Strong binding metal-chelating resins
WO2022235769A1 (en) 2021-05-04 2022-11-10 Sachem, Inc. Strong binding metal-chelating resins using macrocycle molecules
MX2023015070A (es) 2021-06-28 2024-01-17 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
TW202327642A (zh) 2021-08-25 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 一種含融合蛋白的醫藥組成物
KR20240055080A (ko) 2021-09-15 2024-04-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
CA3243623A1 (en) 2022-02-11 2025-01-20 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Immunoconjugated and its use
WO2023163659A1 (en) 2022-02-23 2023-08-31 Aslan Pharmaceuticals Pte Ltd Glycosylated form of anti-il13r antibody
GB202210679D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
CN120077070A (zh) 2022-09-06 2025-05-30 亚狮康私人有限公司 皮炎患者的睡眠缺失或睡眠障碍的治疗
AU2023400451A1 (en) 2022-11-28 2025-05-22 UCB Biopharma SRL Treatment of fibromyalgia
CN120282801A (zh) 2022-12-28 2025-07-08 苏州盛迪亚生物医药有限公司 一种cd40结合分子的组合物及医药用途
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
WO2025143305A1 (ko) * 2023-12-28 2025-07-03 (주)앰틱스바이오 아미노 니코틴아마이드 구조를 포함하는 유도체 화합물 및 이를 포함하는 항진균성 약학적 조성물
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU593611B2 (en) * 1986-02-14 1990-02-15 Nihon Medi-Physics Co., Ltd. High molecular compounds having amino groups, and their utilization
IL83567A (en) * 1986-08-18 1992-02-16 Dow Chemical Co Starburst conjugates with a carried material,such as an agricultural or pharmaceutical material
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
PT95809A (pt) * 1989-11-07 1991-09-13 Bristol Myers Squibb Co Processo para a preparacao de imunoglobulinas oligomericas, nomeadamente anticorpos monoclonais oligomericos
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins

Also Published As

Publication number Publication date
ZA924271B (en) 1993-12-13
CA2088367A1 (en) 1992-12-12
NZ243099A (en) 1996-07-26
FI930580A0 (fi) 1993-02-10
DE69230994T2 (de) 2001-02-01
WO1992022583A3 (en) 1993-04-01
CA2088367C (en) 2002-08-20
JPH06502657A (ja) 1994-03-24
EP0560947A1 (en) 1993-09-22
JP3373849B2 (ja) 2003-02-04
ES2146212T3 (es) 2000-08-01
AU1971692A (en) 1993-01-12
EP0560947B1 (en) 2000-05-03
DE69230994D1 (de) 2000-06-08
WO1992022583A2 (en) 1992-12-23
NO930440L (no) 1993-04-02
DK0560947T3 (da) 2000-08-07
GB9112536D0 (en) 1991-07-31
KR930701490A (ko) 1993-06-11
FI930580A7 (fi) 1993-04-02
FI930580L (fi) 1993-04-02
ATE192457T1 (de) 2000-05-15

Similar Documents

Publication Publication Date Title
NO930440L (no) Tri- og tetravalente monospesifikke antigen-bindingsproteiner
CA2124953A1 (en) Peptides related to prion proteins
DK113389D0 (da) Monoklonale antistoffer
PT712307E (pt) Metodos para controlo da populacao de celulas b
GB2278357B (en) Humanised antibodies directed against A33 antigen
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
SE8601644D0 (sv) Antikroppspreparation riktad mot vissa determinanter i human c3 samt dess anvendning och framstellning
NO941370L (no) Rekombitope peptider
FI900230A0 (fi) Anti-idiotypa antikroppar mot antikroppar mot antigener med hoeg molekylvikt associerade till human melanoma.
WO1995024481A3 (en) Humanized monoclonal antibodies against human interleukin-4
DE69637130D1 (de) Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
ATE94880T1 (de) Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung.
DE3884646D1 (de) Humanes Karcinom-assoziertes Antigen und an dieses Antigen bindende Antikörper.
KR100315596B1 (ko) 인간의 자연형 ＩｇＭ 항체
DE3687542D1 (de) Monoklonaler antikoerper gegen humanes protein c.
GR890100333A (en) Antihuman antigen antibodies
GB2333295A (en) Modified protein G and fragments thereof
NO914094D0 (no) Nytt monoklonalt antistoff mot nytt antigen forbundet medhumantumorer
ATE48638T1 (de) Monoklonaler antikoerper gegen ein humanes tumor- karzinom-assoziiertes antigen.